Table 3.
Dichotomized CD3+ at invasive margin relative to clinicopathologic variables in multivariable Cox proportional hazards models for overall survival by MMR status in stage III colon cancer patients treated with FOLFOX-based adjuvant therapy a
| Variable | MMR-deficient tumors | MMR-proficient tumors | ||||
|---|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |||
| CD3+ at invasive margin (low vs high) | 4.76 (1.43–15.87) | 0.0019 | 3.39 (1.16–9.90) | 0.0103 | ||
| T stage | T3 vs T1–2 T4 vs T1–2 |
—b | 0.0086 | 1.29 (0.38–4.37) 2.72 (0.73–10.13) |
0.0994 | |
| N stage | N2 vs N1 | 4.52 (2.49–8.19) | <.0001 | 3.68 (1.98–6.84) | <.0001 | |
| Histologic grade (high vs low) | 0.77 (0.42–1.43) | 0.3751 | 1.64 (0.90–2.98) | 0.1130 | ||
| Tumor side (left vs right) | 1.13 (0.51–2.51) | 0.7658 | 0.70 (0.36–1.37) | 0.2980 | ||
| Mutation status |
KRAS-mutated vs both wild-type BRAF-mutated vs both wild-type |
0.77 (0.28–2.14) 1.17 (0.58–2.36) |
0.7305 | 1.75 (0.93–3.29) 2.68 (1.03–6.98) |
0.0828 | |
| Smoking (ever vs never) | 0.77 (0.42–1.43) | 0.4031 | 0.88 (0.49–1.57) | 0.6620 | ||
| Age (per 5-year increase) | 1.12 (0.98–1.28) | 0.0980 | 1.25 (1.09–1.43) | 0.0010 | ||
a
CD3+ at invasive margin was dichotomized at an optimized cutpoint value. HRs are adjusted for all variables shown
b
Precise HR could not be estimated since there were no events in the T1–2 subgroup.
Abbreviations: HR, hazard ratio; MMR, mismatch repair